Covid 19 Research Clinical Trials by Shray Alag

Vonoprazan

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (4)

	Name (Synonyms)	Correlation
drug4770	telehealth applications Wiki	0.71
drug4164	Use of mobile application Wiki	0.71
drug3364	Rifampin Wiki	0.35

	Name (Synonyms)	Correlation
drug2374	Midazolam Wiki	0.32

Correlated MeSH Terms (2)

	Name (Synonyms)	Correlation
D018352	Coronavirus Infections NIH	0.05
D045169	Severe Acute Respiratory Syndrome NIH	0.03

Correlated HPO Terms (0)

	Name (Synonyms)	Correlation

Clinical Trials

Navigate: Correlations HPO

There are 2 clinical trials

1 An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers

To determine the time-dependent inhibition potential of repeated doses of oral vonoprazan on the pharmacokinetics (PK) of a single oral dose of midazolam, a sensitive cytochrome P450 3A4 (CYP3A4) substrate, in healthy participants.

NCT04545944

Conditions

Healthy Volunteers

Interventions

Drug: Vonoprazan
Drug: Midazolam

Primary Outcomes

Measure: Area under the plasma midazolam concentration versus time curve from time 0 to the last quantifiable concentration (AUC0-t) following a single dose of midazolam administered alone and coadministered with multiple oral doses of vonoprazan

Time: From within 30 minutes prior to Day 1 midazolam dose up to 24 hours post dose (midazolam administered alone), and from within 30 minutes prior to Day 9 midazolam dose up to 48 hours post dose (midazolam coadministered with vonoprazan)

Measure: Area under the plasma midazolam concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf) following a single dose of midazolam administered alone and coadministered with multiple oral doses of vonoprazan

Measure: Maximum observed plasma midazolam concentration (Cmax) following a single dose of midazolam administered alone and coadministered with multiple oral doses of vonoprazan

2 An Open-Label, Fixed-Sequence, Clinical Drug Interaction Study to Evaluate The Effect of a CYP3A-Inducer, Rifampin, on the Pharmacokinetics of Vonoprazan in Healthy Volunteers

The primary objective of this study is to assess the effect of multiple doses of rifampin on the pharmacokinetics of vonoprazan in healthy participants.

NCT04558216

Conditions

Healthy Participants

Interventions

Drug: Vonoprazan
Drug: Rifampin

Primary Outcomes

Measure: Area Under the Plasma Concentration Versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan

Time: Day 1 and Day 17: 0.25 hours pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 30, 36, and 48 hours post-dose

Measure: Area Under the Plasma Concentration Versus Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan

Time: Day 1 and Day 17: 0.25 hours pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 30, 36, and 48 hours post-dose

Measure: Maximum Observed Plasma Concentration (Cmax) of Vonoprazan

Time: Day 1 and Day 17: 0.25 hours pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 30, 36, and 48 hours post-dose

No related HPO nodes (Using clinical trials)

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

No related HPO nodes (Using clinical trials)

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

CovidResearchTrials

Report Sections

See All Reports

Vonoprazan

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (4)

Correlated MeSH Terms (2)

Correlated HPO Terms (0)

Clinical Trials

1 An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers

NCT04545944

Conditions

Interventions

Primary Outcomes

2 An Open-Label, Fixed-Sequence, Clinical Drug Interaction Study to Evaluate The Effect of a CYP3A-Inducer, Rifampin, on the Pharmacokinetics of Vonoprazan in Healthy Volunteers

NCT04558216

Conditions

Interventions

Primary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

Report Sections

See All Reports

Vonoprazan

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (4)

Correlated MeSH Terms (2)

Correlated HPO Terms (0)

Clinical Trials

1 An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers Click for details

NCT04545944

Conditions

Interventions

Primary Outcomes

2 An Open-Label, Fixed-Sequence, Clinical Drug Interaction Study to Evaluate The Effect of a CYP3A-Inducer, Rifampin, on the Pharmacokinetics of Vonoprazan in Healthy Volunteers Click for details

NCT04558216

Conditions

Interventions

Primary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

1 An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers

2 An Open-Label, Fixed-Sequence, Clinical Drug Interaction Study to Evaluate The Effect of a CYP3A-Inducer, Rifampin, on the Pharmacokinetics of Vonoprazan in Healthy Volunteers